Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients

Ming-Hong Hsieh 1,2, Yi-Liang Wu 1,3, Thomas Chang-Yao Tsao 4, Yi-Wen Huang 5,6, Jian-Cheng Lin 6,7, Chia-Yi Lee 7,8, Ming-Ju Hsieh 9,10,11,* and Shun-Fa Yang 6,7,*

1 School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
2 Department of Psychiatry, Chung Shan Medical University Hospital, Taichung 402, Taiwan
3 Department of Surgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan
4 Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan
5 Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 513, Taiwan
6 Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
7 Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan
8 Nobel Eye Institute, Taipei 115, Taiwan
9 Oral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan
10 Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
11 Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan

* Correspondence: 170780@ccch.org.tw (M.-J.H.); ysf@csmu.edu.tw (S.-F.Y.)

Abstract: The aim of the current study was to evaluate the combined effect of the single nucleotide polymorphism (SNP) in long non-coding RNA growth arrest-specific 5 (GAS5) and the phenotypes of epidermal growth factor receptor (EGFR) on the clinicopathological characteristics of lung adenocarcinoma. The present study examined the relationship between the GAS5 single-nucleotide polymorphisms (SNPs; rs145204276 Ins/Del, rs55829688 T/C) and the clinicopathological factors in 539 lung adenocarcinoma patients with or without EGFR mutations. We found that the genotype distributions of the two GAS5 SNPs between different EGFR genotypes were similar after adjusting for age, gender and smoking history. The GAS5 SNP rs145204276 Ins/Del illustrated a higher distribution with an advanced tumor stage (p = 0.030), larger tumor T status (p = 0.019), positive lymph node status (p = 0.014) and distal metastases (p = 0.011) in the EGFR wild type group. In the subgroup analysis of the EGFR wild type population, the presence of GAS5 SNP rs145204276 Ins/Del + Del/Del was correlated to an advanced tumor stage (p = 0.014) and distal metastases (p = 0.020) in non-smokers. In conclusion, these data indicate that the GAS5 SNP rs145204276 variant may help predict tumor stage, lymph node metastasis and distal metastases in patients with EGFR wild type lung adenocarcinoma.

Keywords: lung cancer; GAS5; polymorphism; EGFR mutation

1. Introduction

Lung adenocarcinoma is a prevalent neoplasm, worldwide which shows a high incidence in all the lung cancer in the Eastern Asian population compared to the American population [1,2]. The treatments for lung adenocarcinoma today include surgical excision, chemotherapy and target therapy [3,4]. Regarding the risk factors for the lung adenocarcinoma, cigarette smoking is a well-known risk factor for lung cancer including adenocarcinoma in which the presence of cigarette smoking history can elevate the risk of lung cancer development about 20–50-fold [5]. Besides, a recent article demonstrated that
the male gender produces a significantly higher risk of grade three lung adenocarcinoma compared to the female population [6].

Certain genetic factors are associated with the development of lung adenocarcinoma and the epidermal growth factor receptor (EGFR) and its mutation is probably the genetic risk factor of lung adenocarcinoma that has been studied most completely [7]. The EGFR mutation L858R expression and exon 19 in-frame deletion are correlated to a higher sensitivity of lung cancer to EGFR tyrosine kinase inhibitors [8]. In addition, the presence of EGFR mutations and the single nucleotide polymorphism (SNP) of Aurora kinase A is associated with earlier tumor stage of the lung adenocarcinoma [9]. Except the EGFR, the long non-coding RNA H19 causes the progression and metastasis of lung cancer [10], and the LAMC1 SNP rs3768617 could also increase the risk of lung cancer [11].

The growth arrest-specific 5 (GAS5) is a type of long non-coding RNA that acts as a tumor suppressor and influences the cell apoptosis and tumorigenesis processes in accordance with previous publications [12–14]. Regarding the SNP of GAS5, the GAS5 SNP rs145204276 increases the probability of larger tumor status in urothelial cell carcinoma [13]. In addition, the GAS5 SNP rs145204276 is significantly correlated with lung cancer susceptibility [15]. However, there are scant studies that discuss the SNP of GAS5 and its correlation to the clinical features of lung adenocarcinoma. Also, because the SNPs of other gene would interact with EGFR genotype and affect the characters of lung adenocarcinoma [9], a similar action may occur between GAS5 SNPs and EGFR which need additional evaluation.

Consequently, the purpose of the current study was to evaluate the effect of GAS5 SNP plus EGFR phenotypes on the clinical manifestations of lung adenocarcinoma. In addition, the subgroup analysis according to the cigarette smoking history in EGFR wild type population was conducted.

2. Materials and Methods

2.1. Patients and Specimens

This research enrolled patients with lung adenocarcinoma and followed up for more than six months in Chung Shan Medical University Hospital and Changhua Hospital and a total of 539 patients were included in the study population. These patients were further categorized into those with EGFR wild type and EGFR mutation, and 221 and 318 patients constituted the two groups respectively. The EGFR mutation in this study included the L858R expression and exon 19 in-frame deletion. The age, gender, and cigarette smoking history of these patients was obtained and a cancer sample of all participants was collected as the form of frozen specimen. Then Tumor, Node, Metastasis (TNM) condition, tumor stages, degree of cell differentiation (i.e., the well-differentiated, the moderately differentiated, and the poorly differentiated) were based on the American Joint Committee on Cancer. This study was adhered to the Declaration of Helsinki in 1964 and later amendments and Institutional Review Boards of Chung Shan Medical University Hospital approved this study (Project code: No. CS18173; 18 February 2019 and CS1-20144, 24 August 2020). Besides, written informed consents were taken from all the participants after explaining and discussing the details of this research. For GAS5 SNP analyses, we took venous blood and preserved it in ethylenediaminetetraacetic acid-containing tubes. The samples were centrifuged and restored in one laboratory refrigerator at –80 degrees Celsius.

2.2. Genomic DNA Extraction and Analysis of GAS5 SNP via Real-Time PCR

Two SNPs of GAS5: rs145204276 (Ins/Del) and rs55829688 (T/C) were chosen due to their effects on lung cancer and other neoplasms [15–17]. The genotyping procedure is referred to in our previous research [18]. The genomic DNA was extracted from leukocytes in venous blood sample via QIAamp DNA kits (Qiagen, Valencia, CA, USA), and all steps with QIAamp DNA kits were in accordance with manufacturer’s instruction. The reason we used leukocytes to take genomic DNA is because it is a simple way to obtain human genomic DNA. Isolated DNA was put in one refrigerator under –20 degrees Celsius. The
two GAS5 SNPs were examined via the ABI StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). After that, the polymorphisms of both GAS5 SNPs were analyzed with the assistance of the TaqMan assay technique as well as the SDS version 3.0 software (Applied Biosystems) to enhance Real-Time PCR completeness.

2.3. Statistical Analysis

The SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was applied. Descriptive analyses such as mean value, standard deviation (SD) and percentage were used to reveal basic characters and laboratory data of the study population. The Chi-squared test and independent t-test were applied for comparing each value between EGFR wild type and EGFR mutation groups. The adjusted odds ratio (AOR) with a 95% confidence interval (CI) of genotype distribution between the EGFR wild type and EGFR mutation population was produced via multiple logistic regression models after controlling for age, gender and cigarette smoking status. In further analyses, the genotypes of rs145204276 (Ins/Del) and rs55829688 (T/C) and their effects on clinicopathological characteristics of lung adenocarcinoma in the EGFR wild type and EGFR mutation population were calculated with corresponding odds ratio (OR) and 95% CI. For the subgroup analysis, the EGFR wild type patients were categorized as non-smokers or ever-smokers and the relationship between GAS5 rs145204276 genotype frequencies and clinicopathological characteristics of lung adenocarcinoma were estimated. The statistically significant level was defined as \( p < 0.05 \).

3. Results

3.1. Basic Characteristics between EGFR Wild Type and EGFR Mutation Groups

The mean age in the EGFR wild type group was 64.63 ± 12.18 years old which was similar to the mean age in the EGFR mutation group (65.45 ± 12.55) \( (p = 0.453) \). On the other hand, a higher female ratio (66.7 versus 38.5%, \( p = 0.001 \)) and lower cigarette smoking rate (19.5 versus 52.9%, \( p = 0.001 \)) were found in the EGFR mutation group. Except for a lower percentage of poor cell differentiation in the EGFR mutation group \( (p < 0.001) \), all tumor characteristics were identical between the two groups (Table 1).

Table 1. Demographics and clinical characteristics of 539 patients in lung adenocarcinoma with EGFR mutation status.

| Variable                      | EGFR Wild Type (N = 221) n (%) | EGFR Mutation (N = 318) n (%) | \( p \) Value |
|-------------------------------|-------------------------------|-------------------------------|-------------|
| Age Mean ± SD                 | 64.63 ± 12.18                 | 65.45 ± 12.55                 | 0.453       |
| Gender                        |                               |                               |             |
| Male                          | 136 (61.5%)                   | 106 (33.3%)                   | 0.001 *     |
| Female                        | 85 (38.5%)                    | 212 (66.7%)                   |             |
| Cigarette smoking status      |                               |                               |             |
| Never-smoker                  | 104 (47.1%)                   | 256 (80.5%)                   | 0.001 *     |
| Ever-smoker                   | 117 (52.9%)                   | 62 (19.5%)                    |             |
| Stage                         |                               |                               |             |
| I+II                          | 49 (22.2%)                    | 76 (23.9%)                    | 0.640       |
| III+IV                        | 172 (77.8%)                   | 242 (76.1%)                   |             |
| Tumor T status                |                               |                               |             |
| T1+T2                         | 109 (49.3%)                   | 171 (53.8%)                   | 0.309       |
| T3+T4                         | 112 (50.7%)                   | 147 (46.2%)                   |             |
| Lymph node status             |                               |                               |             |
| Negative                      | 60 (27.1%)                    | 89 (28.0%)                    | 0.831       |
| Positive                      | 161 (72.9%)                   | 229 (72.0%)                   |             |
| Distant metastasis            |                               |                               |             |
| Negative                      | 98 (44.3%)                    | 127 (39.9%)                   | 0.308       |
| Positive                      | 123 (55.7%)                   | 191 (60.1%)                   |             |
| Cell differentiation          |                               |                               |             |
| Well                          | 19 (8.6%)                     | 35 (11.0%)                    | <0.001 *    |
| Moderately                    | 136 (61.5%)                   | 248 (78.0%)                   |             |
| Poorly                        | 66 (29.9%)                    | 35 (11.0%)                    |             |

N: number; SD: standard deviation; * Denotes significant difference between the two groups.
3.2. Distribution of GAS5 SNPs and EGFR Genotypes in Different Clinical Characters of Lung Adenocarcinoma

The distribution frequencies of GAS5 SNP rs145204276 (Ins/Del) and rs55829688 (T/C) between the EGFR wild type and EGFR mutation groups are shown in Table 2. After adjusting for age, gender and cigarette smoking history, the genotype distributions of the two GAS5 SNPs between different EGFR genotypes were similar (all \( p > 0.05 \)). About the genetic polymorphisms and the clinicopathologic characteristics of lung adenocarcinoma, the GAS5 SNP rs145204276 Ins/Del + Del/Del demonstrated a higher distribution in advanced tumor stage \((p = 0.030)\), larger tumor T status \((p = 0.019)\), positive lymph node status \((p = 0.014)\) and the presence of distal metastasis \((p = 0.011)\) when compared to the GAS5 rs145204276 wild type in the EGFR wild type group (Table 3). On the other hand, there may not be strong relationships between the distribution frequencies of GAS5 SNP rs55829688 and the clinicopathologic characteristics of lung adenocarcinoma in all EGFR genotypes (all \( p > 0.05 \)) (Table 4).

The AORs with 95% CIs were estimated by multiple logistic regression models after controlling for age, gender and cigarette smoking status.

Table 2. Distribution frequency of GAS5 genotypes of patients with lung adenocarcinoma and multiple logistic regression analysis of EGFR mutation association.

| Genotypes | EGFR Wild Type (N = 221) | EGFR Mutation (N = 318) | AOR (95% CI) | \( p \) Value |
|-----------|--------------------------|--------------------------|--------------|--------------|
| rs145204276 | | | | |
| Ins/Ins | 92 (41.6%) | 131 (41.2%) | 1.00 | |
| Ins/Del | 102 (46.2%) | 144 (45.3%) | 0.973 (0.655–1.445) | 0.891 |
| Del/Del | 27 (12.2%) | 43 (13.5%) | 1.064 (0.590–1.920) | 0.836 |
| Ins/Del + Del/Del | 129 (58.4%) | 187 (58.8%) | 0.992 (0.682–1.443) | 0.967 |
| rs55829688 | | | | |
| TT | 100 (45.2%) | 166 (52.2%) | 1.00 | |
| TC | 99 (44.8%) | 121 (38.1%) | 0.787 (0.532–1.163) | 0.229 |
| CC | 22 (10.0%) | 31 (9.7%) | 0.678 (0.356–1.293) | 0.238 |
| TC + CC | 121 (54.8%) | 152 (47.8%) | 0.765 (0.528–1.108) | 0.157 |

N: number; AOR: adjusted odds ratio; CI: confidence interval.

Table 3. Clinicopathologic characteristics of lung adenocarcinoma patients with EGFR mutations, stratified by polymorphic genotypes of GAS5 rs145204276.

| Variable | ALL (N = 539) | EGFR Wild type (N = 221) | EGFR Mutation (N = 318) | \( p \) Value |
|----------|---------------|--------------------------|--------------------------|--------------|
| Stages | | | | |
| I+II | 53 (23.8%) | 72 (22.8%) | 0.790 | |
| III+IV | 170 (76.2%) | 244 (77.2%) | 65 (70.7%) | 107 (82.9%) | 105 (80.2%) | 137 (73.3%) | |
| Tumor T status | | | | |
| T1+T2 | 126 (56.5%) | 154 (48.7%) | 0.075 | |
| T3+T4 | 97 (43.5%) | 162 (51.3%) | 54 (58.7%) | 38 (41.3%) | 74 (57.4%) | 59 (45.0%) | 88 (47.1%) | |
| Lymph node status | | | | |
| Negative | 65 (29.1%) | 84 (26.6%) | 0.512 | |
| Positive | 158 (70.9%) | 252 (73.4%) | 33 (35.9%) | 27 (29.5%) | 20 (15.8%) | 72 (46.5%) | 99 (52.9%) | 0.722 |
| Distant metastasis | | | | |
| Negative | 99 (44.4%) | 126 (39.9%) | 0.294 | |
| Positive | 124 (55.6%) | 190 (60.1%) | 50 (54.3%) | 48 (37.2%) | 102 (79.1%) | 99 (75.6%) | 130 (69.5%) | 0.440 |
| Cell differentiation | | | | |
| Well/Moderately | 179 (80.3%) | 259 (82.0%) | 0.620 | |
| Poorly | 44 (19.7%) | 57 (18.0%) | 62 (67.4%) | 93 (72.1%) | 45 (32.6%) | 36 (27.9%) | 14 (10.7%) | 21 (11.2%) | 0.879 |

N: number; * Denotes significant difference between the two genotypes.
Table 4. Clinicopathologic characteristics of lung adenocarcinoma patients with EGFR mutations, stratified by polymorphic genotypes of GAS5 rs55829688.

| Variable                        | ALL (N = 539) | EGFR Wild Type (N = 221) | p Value | EGFR Mutation (N = 318) | p Value |
|--------------------------------|---------------|---------------------------|---------|-------------------------|---------|
|                                | TT (N = 266)  | TC+CC (N = 273)           |         | TT (N = 100)            | TC+CC (N = 121) | p Value |
| Stages                          |               |                           |         |                         |         |
| I+II                           | 70 (26.3%)    | 55 (20.1%)                | 0.090   | 25 (25.0%)              | 24 (19.8%) | 0.358   |
| III+IV                         | 196 (73.7%)   | 218 (79.9%)               |         | 75 (75.0%)              | 97 (80.2%) | 0.161   |
| Tumor T status                 |               |                           |         |                         |         |
| T1+T2                          | 144 (54.1%)   | 136 (49.8%)               | 0.316   | 52 (52.0%)              | 57 (47.1%) | 0.469   |
| T3+T4                          | 122 (45.9%)   | 137 (50.2%)               |         | 48 (48.0%)              | 64 (52.9%) | 0.161   |
| Lymph node status              |               |                           |         |                         |         |
| Negative                       | 80 (30.1%)    | 69 (25.3%)                | 0.213   | 28 (28.0%)              | 32 (26.4%) | 0.796   |
| Positive                       | 186 (69.9%)   | 204 (74.7%)               |         | 72 (72.0%)              | 89 (73.6%) | 0.161   |
| Distant metastasis             |               |                           |         |                         |         |
| Negative                       | 119 (44.7%)   | 106 (38.8%)               | 0.164   | 50 (50.0%)              | 48 (39.7%) | 0.124   |
| Positive                       | 147 (55.3%)   | 167 (61.2%)               |         | 50 (50.0%)              | 73 (60.3%) | 0.975   |
| Cell differentiation           |               |                           |         |                         |         |
| Well/Moderately                | 217 (81.6%)   | 221 (81.0%)               | 0.852   | 74 (74.0%)              | 81 (66.9%) | 0.254   |
| Poorly                         | 49 (18.4%)    | 52 (19.0%)                |         | 21 (26.0%)              | 47 (33.1%) | 0.125   |

N: number.

3.3. Subgroup Analysis about the Cigarette Smoking Status and GAS5 SNP rs145204276 in EGFR Wild Type

In the subgroup analyses in the EGFR wild type population, the presence of GAS5 SNP rs145204276 Ins/Del + Del/Del may be correlated with an advanced tumor stage (p = 0.014) and distal metastases (p = 0.020) in non-smoker individuals. Moreover, a higher ratio of GAS5 SNP rs145204276 Ins/Del + Del/Del variant was found in the patients with lymph node invasion and cigarette smoking history (p = 0.036). The rest of the outcomes of the subgroup analyses concerning the cigarette smoking status revealed insignificant values (all p > 0.05) (Table 5).

Table 5. GAS5 rs145204276 genotype distribution and clinicopathologic characteristics of EGFR wild type lung adenocarcinoma patients with different cigarette smoking statuses.

| Variable                        | Non-Smoker (N = 104) | Ever-Smoker (N = 117) | p Value |
|--------------------------------|----------------------|-----------------------|---------|
|                                | Ins/Ins (N = 39)     | Ins/Del + Del/Del (N = 65) |         |
| Stages                          |                      |                       |         |
| I+II                           | 15 (38.5%)           | 11 (16.9%)            | 0.014 * | 12 (22.6%)              | 11 (17.2%) | 0.460   |
| III+IV                         | 24 (61.5%)           | 54 (83.1%)            |         | 41 (77.4%)              | 53 (82.8%) | 0.112   |
| Tumor T status                 |                      |                       |         |                         |         |
| T1+T2                          | 23 (59.0%)           | 27 (41.5%)            | 0.085   | 31 (58.5%)              | 28 (43.7%) | 0.112   |
| T3+T4                          | 16 (41.0%)           | 38 (58.5%)            |         | 22 (41.5%)              | 36 (56.3%) | 0.036 * |
| Lymph node status              |                      |                       |         |                         |         |
| Negative                       | 15 (38.5%)           | 16 (24.6%)            | 0.135   | 18 (34.0%)              | 11 (17.2%) | 0.036 * |
| Positive                       | 24 (61.5%)           | 49 (75.4%)            |         | 35 (66.0%)              | 53 (82.8%) | 0.237   |
| Distant metastasis             |                      |                       |         |                         |         |
| Negative                       | 21 (53.8%)           | 20 (30.8%)            | 0.020 * | 29 (54.7%)              | 28 (43.7%) | 0.621   |
| Positive                       | 18 (46.2%)           | 45 (69.2%)            |         | 24 (45.3%)              | 36 (56.3%) | 0.237   |
| Cell differentiation           |                      |                       |         |                         |         |
| Well/Moderately                | 27 (69.2%)           | 48 (73.8%)            | 0.611   | 35 (66.0%)              | 45 (70.3%) | 0.621   |
| Poorly                         | 12 (30.8%)           | 17 (26.2%)            |         | 18 (34.0%)              | 19 (29.7%) | 0.621   |

N: number; * Denotes significant difference between the two genotypes.

4. Discussion

In our study, the GAS5 SNP rs145204276 Ins/Del + Del/Del contributed to worse tumor condition concerning the tumor stage, tumor T status and lymph node status in lung adenocarcinoma patients with EGFR wild type. In more details, the GAS5 SNP...
rs145204276 Ins/Del + Del/Del causes a higher tumor stage and leads to distal metastases in non-smokers with lung adenocarcinoma and wild-type EGFR.

A number of studies had evaluated the association between EGFR and lung adenocarcinoma previously [7]. The two common EGFR mutations that influence the clinical characteristics of lung adenocarcinoma are the L858R expression and exon 19 in-frame deletion [19,20]. According to previous literature, the existence of EGFR L858R expression mutation may cause a better therapeutic outcome of lung adenocarcinoma without other genetic risk factors such as cytoplasmic ERβ1 expression [21]. However, intensive EGFR L858R expression on micropapillary components may increase the recurrence of lung adenocarcinoma [22]. The exon 19 in-frame deletion is another important genetic variant for the clinical course of lung adenocarcinoma in which the EGFR exon 19 in-frame deletion produced a better response to gefitinib and erlotinib in patients with lung adenocarcinoma [23], and another study illustrated that the overall survival in advanced lung adenocarcinoma patients with EGFR exon 19 in-frame deletions was better than those with EGFR L858R expression [24]. In addition, the EGFR exon 20 insertion mutations may change the resistance of lung cancer to EGFR inhibitors [25]. In addition to the genetic variant itself, the EGFR genotypes could show different effects on the clinicopathologic characters of lung adenocarcinoma when combining it with other genetic polymorphisms. For instance, the Aurora kinase A SNP rs6024836 AG + GG is related to an earlier tumor stage if combined with the presence of an EGFR mutation, L858R expression and exon 19 in-frame deletion [9]. Besides, the LncRNA H19 SNP rs217727 are related to advanced tumor status for lung adenocarcinoma with EGFR wild type [26]. On the other side, the GAS5 and its SNP is another genetic risk factor for cardiovascular disease and various malignancies including the lung adenocarcinoma [13,15,27–29]. In the study by Liang et al., the GAS5 expression would reduce in non-small cell lung cancer, which can serve as a biomarker [30], and the GAS5 would lead to lower rate of lung adenocarcinoma invasion and migration [31]. Consequently, the genotypes of these two genetic factors, the EGFR and GAS5, may interact and alter the clinical course of lung adenocarcinoma. The above hypothesis is supported by the results of this study at least to some extent.

Concerning the genetic polymorphism of GAS5 and the clinical characters of lung adenocarcinoma with different EGFR genotypes, the lung adenocarcinoma patients with EGFR wild type and GAS5 SNP rs145204276 Ins/Del + Del/Del would experience higher tumor stage, larger tumor T status, advanced lymph node invasion and distal metastasis compared to those patients without the GAS5 variant. This is a relatively new finding that the SNP of GAS5 can grossly affect the clinicopathological characteristics of lung adenocarcinoma with wild-type EGFR. In other type of cancer, although the GAS5 SNP rs145204276 is related to a lower incidence of tumor progression in gastric cancer and serves as a protector [16,32], the existence of GAS5 SNP rs145204276 may contribute to a worse tumor stage and size in certain subjects with oral cancer [17]. In addition, the GAS5 is a potential target for breast cancer treatment [33]. For the aspect of EGFR, the EGFR wild type is associated with poorer treatment response and progression-free survival compared to their mutation counterpart [34]. Consequently, the double tumorigenic effects of the two genes could increase the tumor progression in the lung adenocarcinoma. On the contrary, the combined effect of EGFR wild type and GAS5 SNP rs145204276 Ins/Del + Del/Del increases neither the percentage of poorly differentiated tumor cells, nor the cell differentiation of the EGFR mutation type. Moreover, the GAS5 SNP rs55829688 TC+CC did not alter all the clinical manifestations of lung adenocarcinoma with all types of the EGFR genotype. The above two findings may indicate that the influence of GAS5 on lung adenocarcinoma is not universal.

In the subgroup analyses of EGFR wild type, the GAS5 SNP rs145204276 Ins/Del + Del/Del are related the tumor stage and distal metastases of lung adenocarcinoma in the non-smoker population and enhance the lymph node invasion of lung adenocarcinoma in the ever-smoker group. Seldom research has reported this specific effect of GAS5 SNP rs145204276 Ins/Del + Del/Del in patients with different smoking histories. The exact
mechanism for this difference remains unknown; maybe the tobacco particles would alter the lymph node condition and make it more vulnerable for lung adenocarcinoma cells under certain genetic polymorphisms. Additionally, the SNPs at 22q12 and the 15q15.2 locus would increase the risk of lung cancer even in non-smokers [35]; maybe the GAS5 SNP rs145204276 Ins/Del + Del/Del owns a similar effect to them. On the other side, all the ratios of worse tumor statuses including tumor stage, tumor T status, lymph node status and distal metastases were silently higher with the presence of GAS5 SNP rs145204276 Ins/Del + Del/Del compared to the GAS5 SNP rs145204276 Ins/Ins wild type. This finding may further imply the prominent effect of GAS5 SNP rs145204276 on the TNM score and tumor stage of lung adenocarcinoma which is in accordance with our findings in the above paragraph. Still, whether the length of cigarette smoking period would interact with GAS5 SNP rs145204276 and alter the clinicopathological characteristics of lung adenocarcinoma needs further validation.

There are certain limitations existing in this study. Firstly, the cross-sectional nature of the study design makes the longitudinal follow up to survey the treatment outcome in different groups and genotypes impossible, and further cohort research that enrolls participants with different genotypes should be conducted. Secondly, the number of patients (539) enrolled in the current study is relatively small compared to the population-based studies that often recruit more than 1000 patients. This smaller sample size may contribute to some bias despite the power of our study population having reached 0.97 and no recruitment difficulty being encountered. Besides, the air-pollution particle is an important risk factor for the lung adenocarcinoma development [1]; we did not collect this data and put it into the multivariable analyses, which may influence the statistical outcome in this study. Nevertheless, all the patients included in this study were from Taichung and Chunghua city in Taiwan, which is an area with severe air pollution. As a consequence, the impact of air-pollution particle exposure on the outcome evaluation in this study might be minimal.

5. Conclusions

In conclusion, the presence of the GAS5 SNP rs145204276 variant could lead to advanced clinicopathological characteristics of lung adenocarcinoma under the presence of the EGFR wild type. Furthermore, the affected clinicopathological characters by GAS5 SNP rs145204276 are different between the non-smokers and ever-smokers. Consequently, the GAS5 genotype analyses in patients with lung adenocarcinoma and EGFR wild type may be suggested to find advanced tumor condition. Further large-scale prospective studies to evaluate whether the GAS5 SNP rs145204276 and other variants would affect the therapeutic outcome in lung adenocarcinoma with wild-type wild type are mandatory.

Author Contributions: Conceptualization, M.-H.H., Y.-L.W. and S.-F.Y.; formal analysis, M.-J.H. and S.-F.Y.; methodology, J.-C.L.; resources, T.C.-Y.T., Y.-W.H. and S.-F.Y.; writing—original draft preparation, M.-H.H., Y.-L.W., C.-Y.L., M.-J.H. and S.-F.Y.; writing—review and editing, M.-H.H., M.-J.H. and S.-F.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study protocol was approved by the Institutional Review Board of Chung Shan Medical University Hospital (No. CS18173; 18 February 2019 and CS1-20144, 24 August 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets generated for this study are available on request to the corresponding authors.

Acknowledgments: We would like to thank the Human Biobank of Chung Shan Medical University Hospital for providing the biological specimen and related clinical data for our research. We like to thank the Yi-Shuan Yu and Ting-Yun Liao for performing part of the PCR genotype.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Yang, D.; Liu, Y.; Bai, C.; Wang, X.; Powell, C.A. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. *Cancer Lett.* 2020, 468, 82–87. [CrossRef] [PubMed]

2. Jakobsen, E.; Olsen, K.E.; Bliddal, M.; Hornbak, M.; Persson, G.F.; Green, A. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. *BMC Cancer* 2021, 21, 985. [CrossRef] [PubMed]

3. Succony, L.; Rassl, D.M.; Barker, A.P.; McCaughan, F.M.; Rintoul, R.C. Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies. *Cancer Treat. Rev.* 2021, 99, 102237. [CrossRef] [PubMed]

4. Ganti, A.K.; Klein, A.B.; Cotarla, I.; Seal, B.; Chou, E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in US. *JAMA Oncol.* 2021, 7, 1824–1832. [CrossRef]

5. Malhotra, J.; Malvezzi, M.; Negri, E.; La Vecchia, C.; Boffetta, P. Risk factors for lung cancer worldwide. *Eur. Respir. J.* 2016, 48, 889–902. [CrossRef]

6. Fujikawa, R.; Muraoka, Y.; Kashima, J.; Yoshida, Y.; Ito, K.; Watanabe, H.; Kusumoto, M.; Watanebe, S.; Yatabe, Y. Clinicopathologic and genotypic features of lung adenocarcinoma characterized by the international association for the study of lung cancer grading system. *J. Thorac. Oncol.* 2022, 17, 700–707. [CrossRef]

7. da Cunha Santos, G.; Shepherd, F.A.; Tsao, M.S. Egfr mutations and lung cancer. *Annu. Rev. Pathol.* 2011, 6, 49–69. [CrossRef]

8. Castellanos, E.; Feld, E.; Horn, L. Driven by mutations: The predictive value of mutation subtype in egfr-mutated non-small cell lung cancer. *J. Thorac. Oncol.* 2017, 12, 612–623. [CrossRef]

9. Yang, P.J.; Hsieh, M.J.; Lee, C.I.; Yen, C.H.; Wang, H.L.; Chiang, W.L.; Lui, T.C.; Tsao, T.C.; Lee, C.Y.; Yang, S.F. Impact of aurora kinase a polymorphism and epithelial growth factor receptor mutations on the clinicopathological characteristics of lung adenocarcinoma. *Int. J. Environ. Res. Public Health* 2020, 17, 7350. [CrossRef]

10. Zhao, Y.; Feng, C.; Li, Y.; Ma, Y.; Cai, R. Lncrna h19 promotes lung cancer proliferation and metastasis by inhibiting mir-200a function. *Mol. Cell Biochem.* 2019, 460, 1–8. [CrossRef]

11. Yu, Y.; Mao, L.; Cheng, Z.; Zhu, X.; Cui, J.; Fu, X.; Cheng, J.; Zhou, Y.; Qiu, A.; Dong, Y.; et al. A novel regqt1-snpr and the risk of lung cancer: A multi-dimensional study. *Arch. Toxicol.* 2021, 95, 3815–3827. [CrossRef]

12. Yang, X.; Xie, Z.; Lei, X.; Gan, R. Long non-coding rna gas5 in human cancer. *Oncol. Lett.* 2020, 20, 2587–2594. [CrossRef]

13. Weng, W.C.; Chen, C.J.; Chen, P.N.; Wang, S.S.; Hsieh, M.J.; Yang, S.F. Impact of gene polymorphisms in gas5 on urothelial cell carcinoma development and clinical characteristics. *Diagnoses 2020, 10, 260. [CrossRef]*

14. Lambrou, G.I.; Hatzigapiou, K.; Zaravinos, A. The non-coding rna gas5 and its role in tumor therapy-induced resistance. *Int. J. Mol. Sci.* 2020, 21, 7633. [CrossRef]

15. Li, W.; Huang, K.; Wen, F.; Cui, G.; Guo, H.; Zhao, S. Genetic variation of lncrna gas5 contributes to the development of lung cancer. *OncoTarget 2017, 8, 91025–91029. [CrossRef]*

16. Li, Q.J.; Ma, G.; Guo, H.M.; Sun, S.H.; Xu, Y.; Wang, B.J. The variant rs145204276 of gas5 is associated with the development and prognosis of gastric cancer. *J. Gastrointest. Liver Dis.* 2018, 27, 19–24. [CrossRef]

17. Hsieh, M.H.; Lu, H.J.; Lin, C.W.; Lee, C.Y.; Yang, S.J.; Wu, P.H.; Chen, M.K.; Yang, S.F. Genetic variants of lncrna gas5 are associated with the clinicopathologic development of oral cancer. *J. Pers. Med.* 2021, 11, 348. [CrossRef]

18. Lee, C.M.; Yang, Y.S.; Kornelius, E.; Huang, C.N.; Hsu, M.Y.; Lee, C.Y.; Peng, S.Y.; Yang, S.F. Association of long non-coding rna growth arrest-specific 5 genetic variants with diabetic retinopathy. *Genes 2022, 13, 584. [CrossRef]*

19. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N. Engl. J. Med.* 2004, 350, 2129–2139. [CrossRef]

20. Paez, J.G.; Jänne, P.A.; Lee, C.J.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science 2004, 304, 1497–1500. [CrossRef]*

21. He, C.; He, Y.; Luo, H.; Zhang, M.; Wu, J.; He, X.; Fu, Y.; Chen, W.; Zou, J. Cytoplasmic erβ1 expression is associated with survival of patients with stage iv lung adenocarcinoma and an egfr mutation at exon 21 l858r subsequent to treatment with egfr-tkis. *Oncol. Lett.* 2019, 18, 792–803. [CrossRef]

22. Kishi, N.; Ito, M.; Miyata, Y.; Kanai, A.; Handa, Y.; Tsutani, Y.; Kushitani, K.; Takeshima, Y.; Okada, M. Intense expression of egfr l858r characterizes the micropapillary component and l858r is associated with the risk of recurrence in pn0m0 lung adenocarcinoma harboring egfr mutations. *J. Thorac. Oncol.* 2011, 7, 65–69. [CrossRef]

23. Ahmed, S.M.; Salgia, R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. *Respirology 2006, 11, 687–692. [CrossRef]*

24. Kim, D.W.; Lee, S.H.; Lee, J.S.; Lee, M.A.; Kang, J.H.; Kim, S.Y.; Shin, S.W.; Kim, H.K.; Heo, D.S. A multicenter phase ii study to evaluate the efficacy and safety of gefitinib as first-line treatment for korean patients with advanced pulmonary adenocarcinoma harboring egfr mutations. *Lung Cancer* 2011, 71, 65–69. [CrossRef]

25. Yasuda, H.; Kobayashi, S.; Costa, D.B. Egfr exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. *Lancet Oncol.* 2012, 13, e23–e31. [CrossRef]

26. Wang, Y.C.; Tsao, S.M.; Li, Y.T.; Lee, C.Y.; Tsao, T.C.; Hsieh, M.J.; Yang, S.F. The relationship between long noncoding rna h19 polymorphism and the epidermal growth factor receptor phenotypes on the clinicopathological characteristics of lung adenocarcinoma. *Int. J. Environ. Res. Public Health* 2021, 18, 2862. [CrossRef]
27. Wang, Y.; Wu, S.; Yang, X.; Li, X.; Chen, R. Association between polymorphism in the promoter region of IncRNA gas5 and the risk of colorectal cancer. *Biosci. Rep.* 2019, 39, BSR20190091. [CrossRef]

28. Lin, C.Y.; Wang, S.S.; Yang, C.K.; Li, J.R.; Chen, C.S.; Hung, S.C.; Chiu, K.Y.; Cheng, C.L.; Ou, Y.C.; Yang, S.F. Impact of gas5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics. *Int. J. Med. Sci.* 2019, 16, 1424–1429. [CrossRef]

29. Jiang, X.; Ning, Q. The mechanisms of IncRNA gas5 in cardiovascular cells and its potential as novel therapeutic target. *J. Drug Target.* 2020, 28, 1012–1017. [CrossRef]

30. Liang, W.; Lv, T.; Shi, X.; Liu, H.; Zhu, Q.; Zeng, J.; Yang, W.; Yin, J.; Song, Y. Circulating long noncoding RNA gas5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer. *Medicine* 2016, 95, e4608. [CrossRef]

31. Zhu, L.; Zhou, D.; Guo, T.; Chen, W.; Ding, Y.; Li, W.; Huang, Y.; Huang, J.; Pan, X. IncRNA gas5 inhibits invasion and migration of lung cancer through influencing EMT process. *J. Cancer* 2021, 12, 3291–3298. [CrossRef] [PubMed]

32. Gao, G.; Liu, C.; Li, X.; Guan, X.; Yang, X.; Qin, P. Growth arrest-specific 5 (gas5) insertion/deletion polymorphism and cancer susceptibility in Asian populations: A meta-analysis. *Medicine* 2021, 100, e27415. [CrossRef] [PubMed]

33. Filippova, E.A.; Fridman, M.V.; Burdenny, A.M.; Loginov, V.I.; Pronina, I.V.; Lukina, S.S.; Dmitriev, A.A.; Braga, E.A. Long noncoding RNA gas5 in breast cancer: Epigenetic mechanisms and biological functions. *Int. J. Mol. Sci.* 2021, 22, 6810. [CrossRef] [PubMed]

34. Stinchcombe, T.E. The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer. *Curr. Treat. Options Oncol.* 2016, 17, 18. [CrossRef]

35. Akhtar, N.; Bansal, J.G. Risk factors of lung cancer in nonsmoker. *Curr. Probl. Cancer* 2017, 41, 328–339. [CrossRef]